Yoon T J, Yoo Y C, Choi O B, Do M S, Kang T B, Lee S W, Azuma I, Kim J B
Animal Resources Research Center College of Animal Husbandry, Kon-Kuk University, Seoul, Korea.
Cancer Lett. 1995 Oct 20;97(1):83-91. doi: 10.1016/0304-3835(95)03956-w.
We examined the inhibitory effect of an aqueous extract (referred to as KM-110) from Viscum album coloratum, a Korean mistletoe, on tumour metastasis produced by highly metastatic murine tumour cells, B16-BL6 melanoma, colon 26-M3.1 carcinoma and L5178Y-ML25 lymphoma cells, using experimental and spontaneous metastasis models in syngeneic mice. In experimental metastasis of B16-BL6 and colon 26-M3.1 cells, intravenous (i.v.) administration of KM-110 (100 micrograms/mouse) 1 day after tumour inoculation significantly inhibited lung metastasis of both tumour cells. The administration of KM-110 also exhibited a therapeutic effect on liver and spleen metastasis of L5178Y-ML25 lymphoma cells. Furthermore, in spontaneous metastasis of B16-BL6 melanoma cells, multiple administration of KM-110 into tumour-bearing mice resulted in significant inhibition of lung metastasis by tumour cells, as well as the suppressive activity to the growth of primary tumour. In in vivo analysis for tumour-induced angiogenesis, the i.v. administration of KM-110 suppressed tumour growth and inhibited the number of blood vessels oriented towards the tumour mass. In a bioassay, the culture supernatant (KM-110-treated medium) of murine peritoneal macrophages that had been stimulated with KM-110 (1-10 micrograms/ml) for 30 min followed by 24 h incubation in fresh medium showed a strong tumour necrosis factor-alpha (TNF-alpha) activity. In addition, KM-110-treated medium significantly inhibited the growth of in vitro cultures of rat lung endothelial (RLE) cells. These results suggested that the extract of Korean mistletoe inhibits tumour metastasis caused by haematogenous as well as non-haematogenous tumour cells, and that its antimetastatic effect results from the suppression of tumour growth and the inhibition of tumour-induced angiogenesis by inducing TNF-alpha.
我们使用同基因小鼠的实验性转移模型和自发性转移模型,研究了韩国槲寄生白果槲寄生的水提取物(称为KM-110)对高转移性小鼠肿瘤细胞、B16-BL6黑色素瘤、结肠26-M3.1癌和L5178Y-ML25淋巴瘤细胞产生的肿瘤转移的抑制作用。在B16-BL6和结肠26-M3.1细胞的实验性转移中,肿瘤接种1天后静脉注射(i.v.)KM-110(100微克/小鼠)可显著抑制两种肿瘤细胞的肺转移。KM-110的给药对L5178Y-ML25淋巴瘤细胞的肝转移和脾转移也具有治疗作用。此外,在B16-BL6黑色素瘤细胞的自发性转移中,对荷瘤小鼠多次给药KM-110可显著抑制肿瘤细胞的肺转移,以及对原发性肿瘤生长的抑制活性。在肿瘤诱导血管生成的体内分析中,静脉注射KM-110可抑制肿瘤生长并减少朝向肿瘤块的血管数量。在生物测定中,用KM-110(1-10微克/毫升)刺激30分钟,然后在新鲜培养基中孵育24小时的小鼠腹腔巨噬细胞的培养上清液(KM-110处理的培养基)显示出强烈的肿瘤坏死因子-α(TNF-α)活性。此外,KM-110处理的培养基显著抑制大鼠肺内皮(RLE)细胞的体外培养生长。这些结果表明,韩国槲寄生提取物可抑制血行性和非血行性肿瘤细胞引起的肿瘤转移,其抗转移作用源于通过诱导TNF-α抑制肿瘤生长和肿瘤诱导的血管生成。